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The term non-Hodgkin lymphoma (NHL) covers a spectrum of malignant disorders arising 
from cells of the immune system and manifesting predominantly as lymphadenopathy or 
solid tumour. The classification of NHL is complex and ever-evolving, with more than 50 
different subtypes listed in the latest WHO classification of lymphoma (1). In this clinical 
update, we address the distinction between low-grade (indolent) and high-grade 
lymphoma, and discuss the principles of diagnosis and management that are of particular 
relevance to the non-specialist physician who may encounter patients with NHL during their 
initial presentation, during therapy and during periods of follow-up. 
 
 
How common is NHL? 
NHL is the 6th commonest malignancy with 13,000 new cases of NHL diagnosed annually in 
the UK (2, 3). The commonest indolent lymphoma is Follicular Lymphoma.  The commonest 
aggressive lymphoma is Diffuse Large B Cell Lymphoma (DLBCL) (Figures 1 & 2). 
 
What causes NHL?    
Most NHLs arise from mature B lymphocytes with a smaller proportion derived from T 
lymphocytes. Lymphoma results from the progressive accumulation of DNA alterations that 
lead to loss of the normal regulatory processes that control cell growth, proliferation and 
survival.  Particular subtypes of lymphoma associate with specific, acquired genetic 
abnormalities; for example the translocation of the BCL2 oncogene in Follicular Lymphoma 
or translocation of the MYC oncogene in Burkitt Lymphoma (4).  
 
Certain subtypes of NHL are associated with infections including Epstein Barr Virus, 
Helicobacter pylori or Hepatitis C(5). NHL is more common in patients who are 
immunosuppressed, such as patients with HIV or recipients of organ transplantation. There 
is a slightly elevated risk in family members but NHL is not generally considered hereditary. 
For the majority of patients presenting with NHL there is no clear aetiological factor.  
 
How do patients with non-Hodgkin lymphoma present? 
NHL commonly presents with lymphadenopathy or splenomegaly. This may develop over 
months or years in low-grade lymphoma but may progress much faster in high-grade 
lymphoma. Lymphoma may also present as a solid, extranodal tumour that may mimic 
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other forms of cancer. Lymphoma may be suspected early if lymphadenopathy is clinically 
detectable. However, in many patients lymphoma is not considered until radiological 
detection of intra-abdominal or thoracic lymphadenopathy. Lymphadenopathy is often 
detected as an incidental finding during investigation of an unrelated condition. Symptoms, 
when present, may result from local compression by the enlarging lymph node or tumour 
mass. Lymphoma may also cause systemic symptoms including fever, sweats and weight 
loss. These are termed “B symptoms”.  They are described in about half of high-grade 
lymphomas but are not specific to the diagnosis. Sweats as an isolated symptom are almost 
never the presenting symptom of lymphoma. Some patients experience pruritus. 
 
Routine blood tests such as renal or liver function may be abnormal if the respective organs 
are involved by lymphoma. Bone marrow involvement may cause anaemia, 
thrombocytopenia and neutropenia. Lactate dehydrogenase (LDH) is often elevated in high-
grade lymphomas but the test is not specific. There is currently no blood test specific for a 
diagnosis of NHL. In many patients presenting with lymphoma all routine blood tests will be 
normal. 
 
Although the presenting features of NHL are diverse the crucial feature prompting suspicion 
of lymphoma is almost always the finding of persistent lymphadenopathy, splenomegaly or 
an extranodal mass. 
 
 
Criteria for and urgency of referral 
In many patients the diagnosis of lymphoma is not initially suspected and referral is made to 
the service most appropriate to investigate their symptoms. However, unexplained lymph 
node enlargement that is persistent, bulky or rapidly enlarging is an indication for referral 
on a suspected cancer pathway.  Local referral pathways vary from region to region but 
patients should be referred to whichever team is most appropriate to arrange biopsy of the 
anatomical location of the lymphadenopathy.  BOX1. 
 
How is the diagnosis of non-Hodgkin lymphoma made?   
Radiology or clinical features may be suggestive of lymphoma, however, a diagnosis of 
lymphoma cannot be made without a biopsy. All patients with lymphadenopathy should 
have a full blood count performed before biopsy to exclude Chronic Lymphocytic 
Leukaemia, as this diagnosis can be made from analysis of the peripheral blood alone. An 
excision lymph node biopsy is preferable (6). Where this is technically challenging a 
radiologically guided core biopsy frequently yields sufficient material for diagnosis.  Fine 
needle aspiration (FNA) is not usually sufficient to allow a diagnosis of lymphoma.  The 
administration of corticosteroids prior to biopsy can make interpretation of lymphoma 
histology extremely difficult and delay diagnosis; corticosteroids should not be given to 
patients with suspected lymphoma without specialist advice. Bone marrow biopsy is 
sometimes performed for staging but is rarely the diagnostic investigation.  A normal bone 
marrow biopsy does not exclude a diagnosis of lymphoma 
 
Lymphoma pathology is complex and should be overseen by a specialist lymphoreticular 
histopathologist in a lymphoma referral centre.  All new diagnoses should be discussed at a 
lymphoma multidisciplinary meeting (MDT). Diagnosis may require iterations of 
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immunohistochemical staining and molecular analysis of chromosomal aberrations by 
fluorescent in situ hybridization.  It is recommended that all new cases are discussed at a 
specialist lymphoma multidisciplinary meeting.   
 
Staging refers to the extent of involvement of the tumour according to the Ann Arbor 
classification [table 1]. Staging is performed by contrast enhanced CT scan of neck to pelvis 
and/or PET-CT scan (Figure 3). For most lymphoma subtypes a pre-treatment prognostic 
score can be assigned.  In DLBCL, the International Prognostic Index (IPI) is calculated based 
upon age, stage, LDH, extranodal disease and performance status(7).  
BOX2 
 
 
How is non-Hodgkin lymphoma treated? 
Management varies from the requirement for no treatment at all through to urgent 
admission for intensive, inpatient chemotherapy. The principles of treatment differ for high-
grade and low-grade lymphoma.  NHL should be managed by a specialist physician who 
forms part of a lymphoma multidisciplinary team in a secondary care setting. 
 
Treatment of high-grade lymphoma  
High-grade NHL may progress rapidly and requires urgent treatment. It is usually treated 
with curative intent using combination chemotherapy, combined, in B-cell tumours, with  
Rituximab, a monoclonal antibody against the B cell-specific surface antigen CD20.  The 
immunochemotherapy regimen most commonly used for DLBCL is R-CHOP (Rituximab, 
Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone).  This is given as an 
outpatient, once every three weeks for a total of 6 cycles.  It is generally well tolerated in 
younger (<75years) patients who are otherwise fit. Several large, randomised studies 
confirmed a survival benefit when Rituximab was added to CHOP (8, 9).  Several large, 
randomised international trials have examined more intensive regimens and the use of 
bone marrow or stem cell transplantation in the first-line treatment of DLBCL(10, 11).  
However, none of these has yet shown a survival improvement over RCHOP.  More intensive 
regimens, given as inpatient treatment, are required to treat Burkitt lymphoma.  More 
intensive regimens are also used to treat high-risk forms of DLBCL, including the so-called 
“double hit” lymphomas (with translocation of both MYC and BCL2 oncogenes). However, 
evidence to support this approach is limited to non-randomised retrospective studies.  After 
completion of immunochemotherapy, patients may be offered localised radiotherapy. 
 
In general patients with high-grade lymphoma respond very well to treatment and high cure 
rates (60-70%) are now achieved(10). During the follow-up period, routine surveillance 
scanning is not warranted and is better targeted at those patients who develop features 
suggestive of relapse. In the absence of relapse, patients are usually discharged from follow-
up after 2-5 years.  Patients with DLBCL who reach 2 years from treatment without relapse 
have a life expectancy equal to that of the age-matched population(12).  
 
Patients who fail first-line chemotherapy are harder to treat.  Those responding to second-
line therapy are consolidated with autologous stem cell transplantation.  
 
Treatment of low-grade lymphomas  
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In contrast to high-grade lymphoma, indolent lymphomas are not considered curable with 
conventional therapy.  An exception is the small number of indolent lymphoma patients 
who present with localised lymphadenopathy.  These patients may be cured by surgical 
excision or by radiotherapy.  However, most indolent lymphoma patients present with 
advanced stage and their lymphoma is best managed as a lifelong, chronic disease. Indolent 
lymphomas tend to progress slowly and, in many patients, present few if any symptoms at 
diagnosis. Randomised trial evidence confirms that early treatment of asymptomatic 
patients with chemotherapy does not prolong their life expectancy(13-15).  Treatment of 
asymptomatic patients with follicular lymphoma with Rituximab may delay the time until 
formal chemotherapy is required but there is no evidence it alters the long-term 
progression of the disease (16).  Therefore, patients diagnosed with indolent lymphoma are 
usually placed on a “watch and wait” policy. Most patients with small volume, 
asymptomatic indolent lymphoma may be safely watched for many years and many will 
never require treatment(15).  
 
Indications to start treatment include: systemic symptoms, bulky lymphadenopathy, 
progressive nodal enlargement, threatened compromise of vital organ function(17). 
Treatment involves immunochemotherapy. In several randomised trials Rituximab improved 
the survival of patients with follicular lymphoma when combined with chemotherapy (18-
20).  Typical first-line regimens include R-CHOP or R-Bendamustine(21). Treatment is given 
as an outpatient for 4-6 months. After chemotherapy is completed, patients typically follow 
a relapsing remitting course with remissions lasting several years. Patients may require 
multiple lines of therapy during their lifetime. Maintenance Rituximab given every two 
months for two years after initial immunochemotherapy increases the length of remission 
but there is currently no evidence of prolonged survival(22). In follicular lymphoma the 
length of first remission is a major determinant of outcome and those patients whose first 
remission is more than two years have excellent outcomes(23). A proportion of patients 
with low-grade lymphomas will transform to high-grade disease (24).  
 
 
What are the complications of chemotherapy? 
Chemotherapy is associated with early and late toxicity, the nature of which depends upon 
the exact treatment used. Patients should expect to receive detailed written information 
about the risks and benefits of their proposed chemotherapy.  
 
Common short-term side effects include temporary hair loss.  Nausea is generally well 
controlled with antiemetic drugs. Changes in taste and loss of appetite are common.  Many 
patients undergoing chemotherapy experience fatigue that can sometimes take many 
months to recover.  Most chemotherapy regimens are myelosuppressive, with potential for 
anaemia, thrombocytopenia and neutropenia. R-CHOP is considered moderately 
myelosuppressive and typically renders patients neutropenic (neutrophil count <1.0) for one 
or two days, usually beginning 7-10 days after each treatment. Neutropenic patients are 
vulnerable to overwhelming bacterial septicaemia. This can be serious or even fatal and 
should be considered a medical emergency.  All patients undergoing chemotherapy should 
receive clear written instructions about how to seek help in the event of fever.  At our 
institution, patients are given written fever rules printed on a red “Chemo Card” along with 
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a 24-hour emergency contact line, which allows emergency admission to the haematology 
unit (Figure 4).    
 
Long-term complications of chemotherapy include peripheral neuropathy, which can 
occasionally be disabling.  Cardiomyopathy is a specific complication of the anthracycline 
component of R-CHOP.  Renal damage may result from nephrotoxic chemotherapy, such as 
the platinum-based drugs as well as from tumour lysis syndrome that may complicate the 
treatment of some high-grade lymphomas. Fertility may be reduced by chemotherapy. 
Where relevant, male patients are offered sperm banking and female patients should be 
offered urgent consultation with a fertility specialist. Both chemotherapy and radiotherapy 
may increase the risk of secondary malignancy. 
 
 
What new treatments can we expect? 
We are rapidly learning more about the molecular and genetic pathogenesis of 
lymphoma(4).  This may allow future treatments to be targeted to genetic subtypes of 
lymphoma.  It has also led to the development of novel, non-chemotherapy drugs that 
target pathways essential for tumour survival. Some show impressive response rates, such 
as Ibrutinib in relapsed mantle cell lymphoma. However, acquired resistance and 
unexpected toxicities are common and it is clear that there is still much to learn in terms of 
how these agents should be deployed. Other agents in clinical trials include T-cells from 
patients that have been genetically modified to recognise lymphoma cells and antibody-
drug conjugates that deliver chemotherapy directly to lymphoma cells. 
 
Patient support and education 
Patients with lymphoma face particular challenges. Those with newly diagnosed indolent 
lymphoma frequently struggle with being told they have a malignant disease but that 
treatment will merely be observation alone. Patients in remission post-treatment frequently 
live in fear that each new symptom they develop could represent a recurrence of their 
disease. Both scenarios can be addressed by adequate patient education and emotional 
support. Trust in the whole multidisciplinary clinical team go a long way to easing patient 
concerns. Specialist nurses play an essential role in this aspect of care, both during clinic 
visits and as an essential point of contact should help or advice be needed between visits.  
Several patient groups and charities provide excellent, free of charge, educational and 
emotional support service for patients, carers and families.  
BOX2 
 
MAIN TEXT WORD COUNT TO HERE:  1998 
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BOX1 
Typical criteria for urgent referral are: 
• Persistent (>6 weeks) lymphadenopathy  
• Lymph nodes greater than 2cm in size 
• Rapidly increasing lymphadenopathy 
• Generalised lymphadenopathy 
 
NICE Guidance (2015): 
“Consider a suspected cancer pathway referral (appointment within 2 weeks) for non-
Hodgkin lymphoma in adults presenting with unexplained lymphadenopathy or 
splenomegaly.  When considering referral take into account any associated symptoms, 
particularly fever, night sweats, shortness of breath, pruritus or weight loss”. 
 
BOX 2 
• Lymphoma Association (LA) produces extremely useful patient literature and has a 
“buddy” scheme that matches newly diagnosed patients with other who have been 
through a similar diagnosis. www.lymphomas.org.uk 
• Macmillan offers medical, psychological and financial support to patients diagnosed 
with cancer. Tel. 0808 808 0000; website: www.macmillan.org.uk.  
• There are several helpful patient groups, such as Facebook “Living with Follicular 
lymphoma” https://www.facebook.com/follicularlymphoma1/.  
• Cancer Research UK provides information about symptoms, risk factors, incidence 
statistics, treatment and trials for NHL.  http://www.cancerresearchuk.org/about-
cancer/non-hodgkin-lymphoma 
 
 
BOX 3 
Outstanding questions and research priorities 
• The management of patients who relapse early or fail to respond to chemotherapy. 
• The management of older or comorbid patients who are unable to tolerate 
chemotherapy. 
• How to prospectively identify and manage patients at high risk of treatment failure. 
• How to identify and provide optimal prophylaxis against central nervous system 
relapse. 
• The role of genomic medicine, novel antibodies and small molecules in the 
treatment of lymphoma. 
 
BOX 4 
What you need to know? 
• NHL is the 6th commonest malignancy and covers a spectrum of histological 
subtypes. 
• Lymphoma may be suspected based on clinical or radiological finding of enlarged 
lymph nodes but the diagnosis is made by tissue biopsy.  
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• The commonest high-grade lymphoma is Diffuse Large B Cell Lymphoma.  It is an 
aggressive malignancy but is curable in 60-70% of patients with combined 
immunochemotherapy. 
• The commonest indolent lymphoma is Follicular Lymphoma.  It is generally 
considered incurable and follows a relapsing remitting course where intermittent 
treatment is required. Patients responding well to chemotherapy have a median 
survival of 20 years. 
• The rapid increase in our understanding of lymphoma biology promises many new 
treatments that may further improve the outlook for patients with NHL. 
• The relapsing and remitting nature of the indolent lymphomas in particular can 
present unique mental health  challenges for patients that are managed by adequate 
patient education and emotional support.  
 
BOX 5 
Educational Resources 
The following organisations produce and publish practice guidelines for the management of 
patients with lymphoma.  The guidelines are available on online and can be accessed free of 
charge. 
 
British Society for Haematology (BSH) Guidelines 
http://www.b-s-h.org.uk/guidelines 
 
EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (EMSO) Guidelines 
http://www.esmo.org/Guidelines/Haematological-Malignancies 
 
National Comprehensive Cancer Network, USA, Clinical Practice Guidelines 
https://www.nccn.org/professionals/physician_gls/default.aspx 
 
NICE Guidelines [NG52] Non-Hodgkin Lymphoma: diagnosis and management July 2016 
https://www.nice.org.uk/guidance/ng52 
 
 
How this article was created. 
We searched Pubmed using the keywords “non-Hodgkin lymphoma”, “diffuse large B cell 
lymphoma” and “follicular lymphoma” to identify reviews and major studies published since 
2000.  This was supplemented by a review of the management guidelines listed in the 
Educational Resources section, by personal experience of the authors and feedback from 
patients. 
 
Patient Involvement 
When designing the content of this article we sought input from the patient group “Living 
with Follicular Lymphoma” and posed the question “what do doctors need to know about 
lymphoma?”   Comments from patients, relatives, and carers influenced the structure of this 
article.  The manuscript was reviewed by a patient who had received treatment for high-
grade lymphoma and by a general practitioner.  Their comments were incorporated into the 
final version, which also includes a case history as described by the patient. 
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Lymphoma from the patient’s perspective.  
 
The story, written by a patient, demonstrates the diverse ways in which lymphoma can 
present, the relapsing remitting nature of indolent lymphoma, its propensity to transform 
into high grade lymphoma and the struggles patients face not only during treatment but 
also whilst in remission. 
 
My lymphoma history. 
It must have come to about 2 years of discomfort and lingering pain in my left side of my 
face and a hard swelling in my left groin when, finally I was referred to the hospital by my 
GP in May 2008.  Subsequently two separate appointments with the ENT for the cheek and 
Ultra Sound for the groin swelling were booked. A biopsy of the swelling of my cheek was 
inconclusive a CT scan and a minor operation to remove the lump followed.  Diagnosis: 
follicular lymphoma and immediate referral to the Oncology Clinic. Chemotherapy with R-
CVP was recommended. The side effects of the chemo set in without hesitation -  nausea, 
vomiting, constipation, weakness, hair loss etc. Hair loss was my least concern – it will grow 
again. Constipation was a pain with ten days without a stool movement.  After six sessions 
of chemotherapy another CT scan showed clearance of the disease. I was in remission. It 
was November 2008. 
 
From then on, I had regular checks and in 2011 the lymphoma returned.  I had noticed for 
some time a swollen leg and pain with an occasional collapse of my right knee joint. I also 
had a skin rash on hands and lower arms. My GP had no explanation for it and suggested 
medication that might make me feel better. Since the next oncology check was due, I said 
that I would mention it to the doctor there. A CT scan and a biopsy were arranged. This time 
the diagnosis was high-grade lymphoma.  My previous follicular lymphoma had now 
“transformed” into something more aggressive, a large mass in the right side of my pelvis 
near the uterus. A total of 6 cycles R-CHOP was prescribed. It was a severe treatment. I had 
to have two blood transfusions during the duration, followed by a course of radiotherapy. 
The side effects seemed to be worse than the ones that I had experienced after my previous 
chemo but I was in remission again.  This time it lasted over five years. The consultant 
suggested discharge, which I declined. My paranoia set in, I was watching every slight 
difference in my body. 
 
Then I detected a lump in my neck under my chin. Another CT scan and then another 
biopsy. This confirmed the original follicular lymphoma was back, but just in one place. This 
time I had radiotherapy. A shield was fitted for me and for 12 days running, except for 
Saturday and Sunday, I had treatment. After that I was very dehydrated due to lack of saliva 
and ulcers in my mouth. I was kept in hospital for 4 days.  The lump had disappeared, but a 
new one on my upper gum then started to grow.  It was cut out and now it was high-grade 
lymphoma again. One shot of radio seems to have done the trick. My last check seemed to 
be clear and I am in remission again and dealing with my paranoia. 
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Figures 
 
Figure 1. Age and gender-specific incidence of non-Hodgkin lymphoma in the UK. Data is 
modified from Cancer Research UK (CRUK) UK cancer incidence statistics 2014. 
 
Figure 2.  Relative incidence of the major subtypes of non-Hodgkin lymphoma based on data 
from Smith et al 2015, Lymphoma incidence, survival and prevalence 2004–2014: sub-type 
analyses from the UK’s Haematological Malignancy Research Network. 
 
Figure 3.  PET-CT image of a patient with Diffuse Large B Cell Lymphoma (DLBCL) before (a) 
and after (b) treatment with 2 courses of R-CHOP chemotherapy. Areas of high intensity 
signal are seen in the left neck, mediastinum, para-aortic and iliac lymph nodes.  Resolution 
is seen in the interim treatment scan.  The high intensity seen in the right ureter and 
bladder represents normal excretion of the tracer. 
 
Figure 4. Example of a “Chemo card” provided to patients undergoing chemotherapy.  It 
includes emergency contact details and instructions to follow in the event of fever. 
 
Table 1 
Early stage 
 
I Single nodal area 
II More than one nodal area, but does not cross the diaphragm 
Advanced 
stage 
III Both sides of diaphragm involved 
IV Extra nodal or bone marrow involvement 
Suffix 
A No B symptoms 
B B symptoms 
E Extranodal disease (localised extranodal disease – Stage 1E) 
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Figure 3.  PET-CT image of a patient with Diffuse Large B Cell Lymphoma (DLBCL) 
before (A) and after (B) treatment with 2 courses of R-CHOP chemotherapy. Areas 
of high intensity signal are seen in the left neck, mediastinum, para-aortic and iliac 
lymph nodes.  Resolution is seen in the interim treatment scan.  The high intensity 
seen in the right ureter and bladder represents excretion of the tracer. 
Figure 4. Example of a “Chemo card” provided to patients undergoing 
chemotherapy.  It includes emergency contact details and instructions to follow 
in the event of fever.
